What difference would an empagliflozin CVD indication make?

When a Food and Drug Administration advisory committee met on June 28 to consider a new indication for the type 2 diabetes drug empagliflozin – reduction of cardiovascular mortality in patients with...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news